<p>Cabaletta Bio（纳斯达克代码：CABA - 获取免费报告）预计将在 2025 年 3 月 12 日星期四市场开盘前发布其 2025 年第四季度财报。分析师预计 Cabaletta Bio 本季度每股收益为（$0.4579）。感兴趣的人士可以访问公司即将发布的 2025 年第四季度财报页面，获取关于定于 2026 年 3 月 27 日星期五上午 8:00（东部时间）电话会议的最新信息。</p>
<p>获取 <strong>Cabaletta Bio</strong> 的提醒：</p>
<h2>Cabaletta Bio 股票上涨 5.5%</h2>
<p>纳斯达克 CABA 周四开盘价为 $3.43。该股票市值为 $3.3017 亿，市盈率为 -1.36，贝塔值为 3.25。Cabaletta Bio 的 52 周低点为 $0.99，52 周高点为 $3.78。该公司的 50 日移动平均价格为 $2.62，200 日移动平均价格为 $2.39。</p>
<h2>内部买卖</h2>
<p>在相关消息中，内部人士 Steve Gavel 于 1 月 21 日星期三购买了 22,170 股公司的股票，交易价格为每股平均$2.27，总价值为$50,325.90。购买后，内部人士持有 22,170 股公司股票，价值约为$50,325.90。该交易使其持股增加了∞。此次收购已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。此外，首席执行官 Steven Nichtberger 于 1 月 21 日星期三购买了 45,000 股 Cabaletta Bio 股票，交易价格为每股平均$2.24，总价值为$100,800.00。收购完成后，首席执行官在公司持有 1,031,483 股，价值约为$2,310,521.92。该交易使其持股增加了 4.56%。此次购买的披露信息可在 SEC 文件中找到。过去三个月，内部人士共购买了 127,668 股公司股票，价值$286,211。目前，11.25% 的股票由公司内部人士持有。</p>
<h2>Cabaletta Bio 的机构交易</h2>
<p>对冲基金最近增加或减少了对该公司的持股。T. Rowe Price Investment Management Inc.在第四季度将其在 Cabaletta Bio 的持股增加了 17.9%。T. Rowe Price Investment Management Inc.目前持有 9,858,257 股公司股票，价值$21,590,000，在此期间又购买了 1,495,768 股。Adage Capital Partners GP L.L.C.在第二季度将其在 Cabaletta Bio 的持股增加了 142.9%。Adage Capital Partners GP L.L.C.目前持有 8,829,758 股公司股票，价值$13,421,000，在上个季度又购买了 5,195,285 股。Vanguard Group Inc.在第三季度将其在 Cabaletta Bio 的持股增加了 21.4%。Vanguard Group Inc.目前持有 4,190,759 股公司股票，价值$9,806,000，在此期间又收购了 740,032 股。Millennium Management LLC 在第四季度将其在 Cabaletta Bio 的持股增加了 298.5%。Millennium Management LLC 目前持有 2,736,912 股公司股票，价值$5,994,000，在上个季度又收购了 2,050,099 股。最后，Superstring Capital Management LP 在第四季度将其在 Cabaletta Bio 的持股增加了 45.9%。Superstring Capital Management LP 目前持有 2,253,550 股公司股票，价值$4,935,000，在上个季度又收购了 709,025 股。</p>
<h2>华尔街分析师预测增长</h2>
<p>另外，Weiss Ratings 在 1 月 21 日星期三的研究报告中重新发布了对 Cabaletta Bio 股票的 “卖出（d-）” 评级。七位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Cabaletta Bio 的平均评级为 “适度买入”，共识目标价为$16.25。</p>
<p><strong>查看我们对 Cabaletta Bio 的最新股票分析</strong></p>
<h2>Cabaletta Bio 公司简介</h2>
<p>（获取免费报告）</p>
<p>Cabaletta Bio 是一家临床阶段的生物技术公司，开创了用于 B 细胞介导的自身免疫疾病的嵌合自抗体受体 T 细胞（CAAR-T）疗法。其专有平台工程化患者来源的 T 细胞，以选择性地靶向和消除产生疾病驱动自抗体的致病 B 细胞，旨在保护整体免疫功能并减少非靶向毒性。</p>
<p>该公司的主要候选药物 DSG3-CAART 正在评估用于治疗天疱疮，这是一种由针对 desmoglein 3 的自抗体引起的罕见水疱性疾病。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更喜欢的五只股票比 Cabaletta Bio 更好</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国 1776 年再次发生</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>用这 4 个简单步骤 “防止美联储影响” 你的银行账户</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FCQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FCQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Cabaletta Bio 吗？</h2>
<p>在你考虑 Cabaletta Bio 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Cabaletta Bio 并不在名单上。</p>
<p>虽然 Cabaletta Bio 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

IBBQ

<p>Cabaletta Bio（纳斯达克代码：CABA）定于 3 月 12 日发布 2025 年第四季度财报，分析师预计每股亏损为 0.4579 美元。该股票上涨了 5.5%，开盘价为 3.43 美元，市值为 3.3017 亿美元。最近的内部交易包括首席执行官 Steven Nichtberger 和内部人士 Steve Gavel 的购买。机构投资者也增加了他们的持股，T. Rowe Price 和 Adage Capital 是其中的知名投资者。Weiss Ratings 给予了 “卖出（d-）” 评级，而共识评级仍为 “适度买入”，目标价为 16.25 美元</p>

<p>Cabaletta Bio (NASDAQ:CABA - Get Free Report) is projected to release its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Cabaletta Bio to post earnings of ($0.4579) per share for the quarter. Interested persons may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 8:00 AM ET.</p>
<div class="lb-trans"><p>Cabaletta Bio（纳斯达克代码：CABA - 获取免费报告）预计将在 2025 年 3 月 12 日星期四市场开盘前发布其 2025 年第四季度财报。分析师预计 Cabaletta Bio 本季度每股收益为（$0.4579）。感兴趣的人士可以访问公司即将发布的 2025 年第四季度财报页面，获取关于定于 2026 年 3 月 27 日星期五上午 8:00（东部时间）电话会议的最新信息。</p>
</div><p>Get <strong>Cabaletta Bio</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cabaletta Bio</strong> 的提醒：</p>
</div><h2>Cabaletta Bio Stock Up 5.5%</h2>
<div class="lb-trans"><h2>Cabaletta Bio 股票上涨 5.5%</h2>
</div><p>NASDAQ CABA opened at $3.43 on Thursday. The stock has a market cap of $330.17 million, a PE ratio of -1.36 and a beta of 3.25. Cabaletta Bio has a fifty-two week low of $0.99 and a fifty-two week high of $3.78. The business has a 50 day moving average price of $2.62 and a two-hundred day moving average price of $2.39.</p>
<div class="lb-trans"><p>纳斯达克 CABA 周四开盘价为 $3.43。该股票市值为 $3.3017 亿，市盈率为 -1.36，贝塔值为 3.25。Cabaletta Bio 的 52 周低点为 $0.99，52 周高点为 $3.78。该公司的 50 日移动平均价格为 $2.62，200 日移动平均价格为 $2.39。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, insider Steve Gavel acquired 22,170 shares of the business's stock in a transaction that occurred on Wednesday, January 21st. The shares were acquired at an average cost of $2.27 per share, with a total value of $50,325.90. Following the purchase, the insider owned 22,170 shares of the company's stock, valued at approximately $50,325.90. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, CEO Steven Nichtberger bought 45,000 shares of Cabaletta Bio stock in a transaction that occurred on Wednesday, January 21st. The stock was bought at an average price of $2.24 per share, with a total value of $100,800.00. Following the completion of the acquisition, the chief executive officer owned 1,031,483 shares in the company, valued at approximately $2,310,521.92. The trade was a 4.56% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 127,668 shares of company stock valued at $286,211 in the last three months. 11.25% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Steve Gavel 于 1 月 21 日星期三购买了 22,170 股公司的股票，交易价格为每股平均$2.27，总价值为$50,325.90。购买后，内部人士持有 22,170 股公司股票，价值约为$50,325.90。该交易使其持股增加了∞。此次收购已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。此外，首席执行官 Steven Nichtberger 于 1 月 21 日星期三购买了 45,000 股 Cabaletta Bio 股票，交易价格为每股平均$2.24，总价值为$100,800.00。收购完成后，首席执行官在公司持有 1,031,483 股，价值约为$2,310,521.92。该交易使其持股增加了 4.56%。此次购买的披露信息可在 SEC 文件中找到。过去三个月，内部人士共购买了 127,668 股公司股票，价值$286,211。目前，11.25% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Trading of Cabaletta Bio</h2>
<div class="lb-trans"><h2>Cabaletta Bio 的机构交易</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. lifted its position in Cabaletta Bio by 17.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,858,257 shares of the company's stock worth $21,590,000 after purchasing an additional 1,495,768 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of Cabaletta Bio by 142.9% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company's stock valued at $13,421,000 after buying an additional 5,195,285 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Cabaletta Bio by 21.4% during the 3rd quarter. Vanguard Group Inc. now owns 4,190,759 shares of the company's stock worth $9,806,000 after acquiring an additional 740,032 shares during the period. Millennium Management LLC boosted its position in shares of Cabaletta Bio by 298.5% during the 4th quarter. Millennium Management LLC now owns 2,736,912 shares of the company's stock valued at $5,994,000 after acquiring an additional 2,050,099 shares in the last quarter. Finally, Superstring Capital Management LP boosted its position in shares of Cabaletta Bio by 45.9% during the 4th quarter. Superstring Capital Management LP now owns 2,253,550 shares of the company's stock valued at $4,935,000 after acquiring an additional 709,025 shares in the last quarter.</p>
<div class="lb-trans"><p>对冲基金最近增加或减少了对该公司的持股。T. Rowe Price Investment Management Inc.在第四季度将其在 Cabaletta Bio 的持股增加了 17.9%。T. Rowe Price Investment Management Inc.目前持有 9,858,257 股公司股票，价值$21,590,000，在此期间又购买了 1,495,768 股。Adage Capital Partners GP L.L.C.在第二季度将其在 Cabaletta Bio 的持股增加了 142.9%。Adage Capital Partners GP L.L.C.目前持有 8,829,758 股公司股票，价值$13,421,000，在上个季度又购买了 5,195,285 股。Vanguard Group Inc.在第三季度将其在 Cabaletta Bio 的持股增加了 21.4%。Vanguard Group Inc.目前持有 4,190,759 股公司股票，价值$9,806,000，在此期间又收购了 740,032 股。Millennium Management LLC 在第四季度将其在 Cabaletta Bio 的持股增加了 298.5%。Millennium Management LLC 目前持有 2,736,912 股公司股票，价值$5,994,000，在上个季度又收购了 2,050,099 股。最后，Superstring Capital Management LP 在第四季度将其在 Cabaletta Bio 的持股增加了 45.9%。Superstring Capital Management LP 目前持有 2,253,550 股公司股票，价值$4,935,000，在上个季度又收购了 709,025 股。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Cabaletta Bio in a research report on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Cabaletta Bio has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $16.25.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 1 月 21 日星期三的研究报告中重新发布了对 Cabaletta Bio 股票的 “卖出（d-）” 评级。七位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Cabaletta Bio 的平均评级为 “适度买入”，共识目标价为$16.25。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Cabaletta Bio</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Cabaletta Bio 的最新股票分析</strong></p>
</div><h2>Cabaletta Bio Company Profile</h2>
<div class="lb-trans"><h2>Cabaletta Bio 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.</p>
<div class="lb-trans"><p>Cabaletta Bio 是一家临床阶段的生物技术公司，开创了用于 B 细胞介导的自身免疫疾病的嵌合自抗体受体 T 细胞（CAAR-T）疗法。其专有平台工程化患者来源的 T 细胞，以选择性地靶向和消除产生疾病驱动自抗体的致病 B 细胞，旨在保护整体免疫功能并减少非靶向毒性。</p>
</div><p>The company's lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.</p>
<div class="lb-trans"><p>该公司的主要候选药物 DSG3-CAART 正在评估用于治疗天疱疮，这是一种由针对 desmoglein 3 的自抗体引起的罕见水疱性疾病。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Cabaletta Bio</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Cabaletta Bio 更好</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国 1776 年再次发生</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>用这 4 个简单步骤 “防止美联储影响” 你的银行账户</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FCQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CABA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cabaletta Bio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Cabaletta Bio 吗？</h2>
</div><p>Before you consider Cabaletta Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Cabaletta Bio 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabaletta Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Cabaletta Bio 并不在名单上。</p>
</div><p>While Cabaletta Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cabaletta Bio 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Cabaletta Bio (CABA) 将在周四公布季度收益报告